Business Wire08.09.19
MedX Health Corp. has signed a non-exclusive, performance-based distribution agreement with Group Vida, to distribute MedX’s DermSecure skin cancer assessment technology platform in the United States, Canada, and Israel.
MedX has previously signed an exclusive distribution agreement for Brazil with CBD Vida LTDA, a partner of Group Vida. The process for regulatory approval in Brazil is proceeding extremely well according to Peter Abboud, Group Vida’s CEO.
“The Brazilian team has already received strong expressions of interest for MedX’s technology once regulatory approval has been granted,” noted Abboud. “CBD Vida has worked very effectively with the Brazilian Health Ministry and private health insurers to garner strong support of MedX’s offering”. According to published research, skin cancer is caught in the later stages in Brazil, and the need for early detection is an issue that is top of mind with the Health Ministry. MedX’s DermSecureTM technology is focused on early detection and seen as a way of preventing and reversing this trend.
Group Vida and its associates have experience in marketing and deploying medical devices and healthcare solutions globally. Group Vida has been actively premarketing MedX’s technology with their healthcare networks in the United States, Canada, and Israel. The results of this marketing effort have identified a number of large distribution partners, pharmacies and healthcare facilities with which Group Vida already has a working relationship. “MedX was pleased to continue to deepen the partnership with Group Vida given their strong interest and understanding of DermsecureTM and their large network of potential customers,” commented Scott Spearn, MedX’s president and CEO.
Abboud stated, “The acceptance of MedX’s technology with our existing healthcare network has been overwhelming. Skin cancer is becoming an epidemic as the population ages and having a point of care technology that offers a rapid assessment for skin cancer fits with the new digital healthcare model. Group Vida exists to bring solutions to our vast Healthcare network and MedX’s DermSecure skin assessment platform and its scalability allows us to bring this offering to our larger existing customers.”
MedX, headquartered in Mississauga, Ontario, is a medical device and software company focused on skin cancer with its DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include handheld devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, U.S. Food and Drug Administration, ARTG and CE cleared for use in Canada, the United States, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.
The founders of Group Vida, combined with their global partners, form a partnership that brings over a quarter century of professional, corporate, organizational, legal and training expertise. Group Vida’s experience has its roots in healthcare, pharmaceuticals, distribution, legal, governmental relations, and finance. These distinctive skills sets integrate and allow Group Vida to identify and exploit market opportunities in the global healthcare space. The partners have an understanding of the world healthcare markets, which is why they formed strategic alliances to introduce proprietary, timely medical and lifestyle products to the world.
MedX has previously signed an exclusive distribution agreement for Brazil with CBD Vida LTDA, a partner of Group Vida. The process for regulatory approval in Brazil is proceeding extremely well according to Peter Abboud, Group Vida’s CEO.
“The Brazilian team has already received strong expressions of interest for MedX’s technology once regulatory approval has been granted,” noted Abboud. “CBD Vida has worked very effectively with the Brazilian Health Ministry and private health insurers to garner strong support of MedX’s offering”. According to published research, skin cancer is caught in the later stages in Brazil, and the need for early detection is an issue that is top of mind with the Health Ministry. MedX’s DermSecureTM technology is focused on early detection and seen as a way of preventing and reversing this trend.
Group Vida and its associates have experience in marketing and deploying medical devices and healthcare solutions globally. Group Vida has been actively premarketing MedX’s technology with their healthcare networks in the United States, Canada, and Israel. The results of this marketing effort have identified a number of large distribution partners, pharmacies and healthcare facilities with which Group Vida already has a working relationship. “MedX was pleased to continue to deepen the partnership with Group Vida given their strong interest and understanding of DermsecureTM and their large network of potential customers,” commented Scott Spearn, MedX’s president and CEO.
Abboud stated, “The acceptance of MedX’s technology with our existing healthcare network has been overwhelming. Skin cancer is becoming an epidemic as the population ages and having a point of care technology that offers a rapid assessment for skin cancer fits with the new digital healthcare model. Group Vida exists to bring solutions to our vast Healthcare network and MedX’s DermSecure skin assessment platform and its scalability allows us to bring this offering to our larger existing customers.”
MedX, headquartered in Mississauga, Ontario, is a medical device and software company focused on skin cancer with its DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include handheld devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, U.S. Food and Drug Administration, ARTG and CE cleared for use in Canada, the United States, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.
The founders of Group Vida, combined with their global partners, form a partnership that brings over a quarter century of professional, corporate, organizational, legal and training expertise. Group Vida’s experience has its roots in healthcare, pharmaceuticals, distribution, legal, governmental relations, and finance. These distinctive skills sets integrate and allow Group Vida to identify and exploit market opportunities in the global healthcare space. The partners have an understanding of the world healthcare markets, which is why they formed strategic alliances to introduce proprietary, timely medical and lifestyle products to the world.
